An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Incyte to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Incyte to present at investor conferences in November
Positive
Incyte will present at the Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference on November 7 at 1:10 pm EST
Incyte will present at the Evercore ISI 6th Annual HealthCONx Conference on November 30 at 12:30 pm EST
Negative
None.
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:
Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST)
Evercore ISI 6th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST)
The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
